-
Je něco špatně v tomto záznamu ?
Future Perspective of Diabetic Animal Models
S. Pandey, MC. Dvorakova,
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články, přehledy
- MeSH
- diabetes mellitus 2. typu chemicky indukované farmakoterapie genetika MeSH
- druhová specificita MeSH
- experimentální diabetes mellitus chemicky indukované farmakoterapie MeSH
- hypoglykemika farmakologie MeSH
- lidé MeSH
- mutantní kmeny myší MeSH
- myši inbrední C57BL MeSH
- myši inbrední NOD MeSH
- potkani inbrední BB MeSH
- potkani inbrední LEW MeSH
- potkani Zucker MeSH
- předpověď MeSH
- preklinické hodnocení léčiv trendy MeSH
- streptozocin MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
OBJECTIVE: The need of today's research is to develop successful and reliable diabetic animal models for understanding the disease susceptibility and pathogenesis. Enormous success of animal models had already been acclaimed for identifying key genetic and environmental factors like Idd loci and effects of microorganisms including the gut microbiota. Furthermore, animal models had also helped in identifying many therapeutic targets and strategies for immune-intervention. In spite of a quite success, we have acknowledged that many of the discovered immunotherapies are working on animals and did not have a significant impact on human. Number of animal models were developed in the past to accelerate drug discovery pipeline. However, due to poor initial screening and assessment on inequivalent animal models, the percentage of drug candidates who succeeded during clinical trials was very low. Therefore, it is essential to bridge this gap between pre-clinical research and clinical trial by validating the existing animal models for consistency. RESULTS AND CONCLUSION: In this review, we have discussed and evaluated the significance of animal models on behalf of published data on PUBMED. Amongst the most popular diabetic animal models, we have selected six animal models (e.g. BioBreeding rat, "LEW IDDM rat", "Nonobese Diabetic (NOD) mouse", "STZ RAT", "LEPR Mouse" and "Zucker Diabetic Fatty (ZDF) rat" and ranked them as per their published literature on PUBMED. Moreover, the vision and brief imagination for developing an advanced and robust diabetic model of 21st century was discussed with the theme of one miceone human concept including organs-on-chips.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028633
- 003
- CZ-PrNML
- 005
- 20210114154522.0
- 007
- ta
- 008
- 210105s2020 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1871530319666190626143832 $2 doi
- 035 __
- $a (PubMed)31241444
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Pandey, Shashank $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 245 10
- $a Future Perspective of Diabetic Animal Models / $c S. Pandey, MC. Dvorakova,
- 520 9_
- $a OBJECTIVE: The need of today's research is to develop successful and reliable diabetic animal models for understanding the disease susceptibility and pathogenesis. Enormous success of animal models had already been acclaimed for identifying key genetic and environmental factors like Idd loci and effects of microorganisms including the gut microbiota. Furthermore, animal models had also helped in identifying many therapeutic targets and strategies for immune-intervention. In spite of a quite success, we have acknowledged that many of the discovered immunotherapies are working on animals and did not have a significant impact on human. Number of animal models were developed in the past to accelerate drug discovery pipeline. However, due to poor initial screening and assessment on inequivalent animal models, the percentage of drug candidates who succeeded during clinical trials was very low. Therefore, it is essential to bridge this gap between pre-clinical research and clinical trial by validating the existing animal models for consistency. RESULTS AND CONCLUSION: In this review, we have discussed and evaluated the significance of animal models on behalf of published data on PUBMED. Amongst the most popular diabetic animal models, we have selected six animal models (e.g. BioBreeding rat, "LEW IDDM rat", "Nonobese Diabetic (NOD) mouse", "STZ RAT", "LEPR Mouse" and "Zucker Diabetic Fatty (ZDF) rat" and ranked them as per their published literature on PUBMED. Moreover, the vision and brief imagination for developing an advanced and robust diabetic model of 21st century was discussed with the theme of one miceone human concept including organs-on-chips.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a experimentální diabetes mellitus $x chemicky indukované $x farmakoterapie $7 D003921
- 650 _2
- $a diabetes mellitus 2. typu $x chemicky indukované $x farmakoterapie $x genetika $7 D003924
- 650 _2
- $a preklinické hodnocení léčiv $x trendy $7 D004353
- 650 _2
- $a předpověď $7 D005544
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x farmakologie $7 D007004
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a myši inbrední NOD $7 D016688
- 650 _2
- $a mutantní kmeny myší $7 D008817
- 650 _2
- $a potkani inbrední BB $7 D011913
- 650 _2
- $a potkani inbrední LEW $7 D011917
- 650 _2
- $a potkani Zucker $7 D011924
- 650 _2
- $a druhová specificita $7 D013045
- 650 _2
- $a streptozocin $7 D013311
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dvorakova, Magdalena C $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Department of Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 773 0_
- $w MED00174280 $t Endocrine, metabolic & immune disorders drug targets $x 2212-3873 $g Roč. 20, č. 1 (2020), s. 25-38
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31241444 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114154518 $b ABA008
- 999 __
- $a ok $b bmc $g 1608968 $s 1119813
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 20 $c 1 $d 25-38 $e - $i 2212-3873 $m Endocrine, metabolic & immune disorders drug targets $n Endocr Metab Immune Disord Drug Targets $x MED00174280
- LZP __
- $a Pubmed-20210105